Abstract
Heme oxygenase-1 (HO-1) is central to the regulation of oxidative injury. The role of increased HO-1 expression and Heme oxygenase (HO) activity in mitigating the detrimental side effect of diabetes is examined. A review of the mechanism(s) of action is included. This may lead to the development of pharmacological and genetic approaches to mitigate the clinical complications associated with the progression of diabetes and obesity.
Keywords: Diabetes, Carbon monoxide, bilirubin, HO-1, Inflamation, TNF, IL-1, adiponectin
Current Pharmaceutical Design
Title: Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Volume: 14 Issue: 5
Author(s): N. G. Abraham, P. L. Tsenovoy, J. McClung and G. S. Drummond
Affiliation:
Keywords: Diabetes, Carbon monoxide, bilirubin, HO-1, Inflamation, TNF, IL-1, adiponectin
Abstract: Heme oxygenase-1 (HO-1) is central to the regulation of oxidative injury. The role of increased HO-1 expression and Heme oxygenase (HO) activity in mitigating the detrimental side effect of diabetes is examined. A review of the mechanism(s) of action is included. This may lead to the development of pharmacological and genetic approaches to mitigate the clinical complications associated with the progression of diabetes and obesity.
Export Options
About this article
Cite this article as:
Abraham G. N., Tsenovoy L. P., McClung J. and Drummond S. G., Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity, Current Pharmaceutical Design 2008; 14 (5) . https://dx.doi.org/10.2174/138161208783597371
DOI https://dx.doi.org/10.2174/138161208783597371 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Geriatric Psychopharmacology in Acute Settings
Current Psychopharmacology Myocardial Energy Transport and Heart Failure
Current Cardiology Reviews QT Alterations in Psychopharmacology: Proven Candidates and Suspects
Current Drug Safety EDITORIAL [Hot Topic: Diabetes Cardiovascular Complications (Guest Editor: Costanza Emanueli)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Current Pharmaceutical Design Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Anthracycline-Induced Cardiotoxicity
Cardiovascular & Hematological Agents in Medicinal Chemistry Pompe Disease and Autophagy: Partners in Crime, or Cause and Consequence?
Current Medicinal Chemistry Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Hyperpolarized Metabolic MR in the Study of Cardiac Function and Disease
Current Pharmaceutical Design Biology and Regulatory Roles of Nuclear Lamins in Cellular Function and Dysfunction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design Diabetic Complications: An Update on Pathobiology and Therapeutic Strategies
Current Diabetes Reviews Genetics and Gene Therapy of Anderson-Fabry Disease
Current Gene Therapy Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management
Current Pharmaceutical Design Genetics of Ion Channels in Sudden Unexplained Death Syndrome: Moving Beyond Idiopathic Reactions To Personalized Risk Assessment
Current Pharmacogenomics and Personalized Medicine New Approach to Immunotherapy Against Organ-specific Autoimmune Diseases with T Cell Receptor and Chemokine Receptor DNA Vaccines
Current Drug Targets - Immune, Endocrine & Metabolic Disorders